Placental growth factor attenuates suppression of erythroid colony formation by interferon

Translational Research

Volumn 152, Issue 5, 2008, Pages 233-238

  Dallalio, Gail ^a   Means Jr , Robert T ^a  

^a LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; FAS LIGAND; INTERFERON; NEUTRALIZING ANTIBODY; PLACENTAL GROWTH FACTOR; RECOMBINANT GAMMA INTERFERON; RECOMBINANT PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CELL LINE; CELL STRAIN HCD57; COLONY FORMING UNIT; CONTROLLED STUDY; ERYTHROID CELL; FETAL CALF SERUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SICKLE CELL;

EID: 57649087000     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.10.001     Document Type: Article

References (32)

1. Platt O.S. Sickle cell anemia as an inflammatory disease. J Clin Invest 106 (2000) 337-338
2. Kaul D.S., and Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 106 (2000) 411-420
3. Miller S.T., Sleeper L.A., Pegelow C.H., Enos L.E., Wang W.C., Weiner S.J., et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 342 (2000) 83-89
4. Means R.T., Dessypris E.N., and Krantz S.B. Inhibition of human colony-forming units erythroid by tumor necrosis factor requires accessory cells. J Clin Invest 86 (1990) 538-541
5. Means R.T., Dessypris E.N., and Krantz S.B. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 150 (1992) 59-64
6. Means R.T. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2 (2003) 116-121
7. Oura H., Bertoncini J., Velasco P., Brown L.F., Carmeliet P., and Detmar M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 101 (2004) 560-567
8. Vercellotti G.M. PlGF: a link between inflammation and angiogenesis in sickle disease. Blood 102 (2003) 1153
9. Perelman N., Selvaraj S.K., Batra S., Luck L.R., Edreich-Epstein A., Coates T.D., et al. Placenta growth factor activates monocytes and correlates with sickle cell disease activity. Blood 102 (2003) 1506-1514
10. Duits A.J., Rodriguez T., and Schnog J.J. Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease. Br J Haematol 134 (2006) 116-119
11. Dallalio G., Brunson C.Y., and Means Jr. R.T. Cytokine concentrations in bone marrow of stable sickle cell anemia patients. J Invest Med 55 (2007) 69-74
12. McLeod D.L., Shreeve M.M., and Axelrad A.A. Improved plasma culture system for production of erytrocytic colonies in vitro: quantitative assay method for CFU-E. Blood 44 (1974) 517-534
13. Eaves A.C., and Eaves C.J. Erythropoiesis in culture. Clin Haematol 13 (1984) 371-391
14. Dai C.H., Price J.O., Brunner T., and Krantz S.B. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon (gamma) to produce erythroid cell apoptosis. Blood 91 (1998) 1235-1242
15. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8 (2002) 831-840
16. Bae D.G., Kim T.D., Li G., Yoon W.H., and ChaeAnti-Flt1 peptide C.B. a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin Cancer Res 11 (2005) 2651-2661
17. Means R.T., and Krantz S.B. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 91 (1993) 416-419
18. Ganz T. The role of hepcidin in iron sequestration during infections and in the pathogenesis of anemia of chronic disease. Isr Med Assoc J 4 (2002) 1043-1045
19. Baer A.N., Dessypris E.N., Goldwasser E., and Krantz S.B. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Brit J Haematol 66 (1987) 559-564
20. Miller C.B., Jones R.J., Piantadosi S., Abeloff M.D., and Spivak J.L. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322 (1990) 1689-1692
21. Singhal A., Cook J.D., Skikne B.S., Thomas P., Serjeant B., and Serjeant G. The clinical significance of serum transferrin receptor levels in sickle cell disease. Brit J Haematol 84 (1993) 301-304
22. Tancabelic J., Sheth S., Paik M., and Piomelli S. Serum transferrin receptor as a marker of erythropoiesis suppression in patients on chronic transfusion. Am J Hematol 60 (1999) 121-125
23. Ballas S.K., and Marcolina M.J. Determinants of red cell survival and erythropoietic activity in patients with sickle cell anemia in the steady state. Hemoglobin 24 (2000) 277-286
24. Dallalio G., North M., and Means R.T. Inhibition of marrow CFU-E colony formation from human immunodeficiency virus-infected patients by β- and γ-interferon. Am J Hematol 53 (1996) 118-120
25. Cai J., Ahmad S., Jiang W.G., Huang J., Kontos C.D., Boulton M., et al. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 52 (2003) 2959-2968
26. Cerdan C., Rouleau A., and Bhatia M. VEGF-A165 augments erythropoietic development from human embryonic stem cells. Blood 103 (2004) 2504-2512
27. Hattori K., Heissig B., Wu Y., Dias S., Tejada R., Ferris B., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 8 (2002) 841-849
28. Martin R., Lahlil R., Damert A., Miquerol L., Nagy A., Keller G., et al. SCL interacts with VEGF to suppress apoptosis at the onset of hematopoiesis. Development 131 (2004) 693-702
29. Tam B.Y., Wei K., Rudge J.S., Hoffman J., Holash J., Park S.K., et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12 (2006) 793-800
30. Tordjman R., Delaire S., Plout J., Ting S., Gaulard P., Fichelson S., et al. Erythroblasts are a source of angiogenic factors. Blood 97 (2001) 1968-1974
31. Janer J., Andersson S., Haglund C., Karikoski R., and Lassus P. Placental growth factor and vascular endothelial growth factor receptor-2 in human lung development. Pediatrics 122 (2008) 340-346
32. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131 (2007) 463-475